Aktis Oncology, Inc.

Aktis Oncology, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapies for solid tumors. Its platform centers on miniprotein radioconjugates designed to deliver alpha-emitting radioisotopes to specific cancer targets, with programs aimed at multiple tumor types.

— Aktis Oncology, Inc.
%
Lead radiopharmaceutical candidate0% Clinical-stage alpha-emitting radioconjugate programs designed for specific tumor targets.
Preclinical pipeline0% Discovery and IND-enabling programs for additional targeted oncology candidates.
Platform technology0% Miniprotein radioconjugate platform used to identify and advance new tumor targets.
Collaboration revenue100% Revenue recognized from research collaboration agreements with strategic partners.

Aktis Oncology’s direct customers are primarily collaboration partners and, eventually, oncology physicians and cancer...

  • Strategic collaboration partnersprimary

    Biopharma partners that fund or co-develop radiopharmaceutical programs and share development risk.

  • Oncology treatment centerssecondary

    Specialty cancer centers that would administer approved radiopharmaceutical therapies.

  • Patients with target-expressing solid tumorsprimary

    Patients whose tumors express Nectin-4, B7-H3, or other selected targets.

  • Nuclear medicine and radiopharmacy networkssecondary

    Specialized sites that would handle isotope preparation, handling, and administration.

Aktis Oncology is headquartered in the United States and conducts its research, development, and corporate activities...

  • •Headquartered and operated from the United States
  • •Clinical development and corporate functions are U.S.-based
  • •Future commercialization could extend to multiple markets
  • •Supply chain depends on external vendors and isotope sources
  • •No country-level revenue disclosure beyond collaboration revenue

The company is focused on broadening targeted radiopharmaceuticals beyond the best-known tumor targets by advancing...

01
Advance lead and follow-on radiopharmaceutical candidatesshort-term

Clinical progress is required to validate the platform and create future product value.

02
Build manufacturing and isotope supply capabilitiesmedium-term

Reliable access to 225Ac and production capacity is essential for trials and eventual commercialization.

03
Expand partnerships and non-dilutive funding sourcesshort-term

Development-stage oncology programs require substantial capital before product revenue exists.

Aktis Oncology faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory...

critical

Clinical development failure

The company has no approved products and depends on successful trial outcomes to create value.

Scope
Lead and pipeline candidates
Materiality
high
high

Radioisotope supply constraints

The business requires sufficient 225Ac and related isotopes to run trials and support future supply.

Scope
Clinical and commercial production
Materiality
high
high

Manufacturing and scale-up execution

Radiopharmaceuticals require specialized handling, production, and logistics capabilities.

Scope
Facility, vendors, and supply chain
Materiality
high
high

Financing and dilution risk

Development-stage operations require ongoing capital before product sales begin.

Scope
Equity, debt, and collaboration funding
Materiality
high
medium

Competitive pressure

Other companies are developing targeted radiopharmaceuticals and oncology therapies for similar markets.

Scope
Target selection and platform differentiation
Materiality
medium
Collaboration revenue recognition
Can create uneven quarterly revenue recognition
Research and development expense timing
Affects operating loss comparability across periods
Contingent milestone and royalty obligations
Potential future cash outflows and expense recognition
Stock-based compensation
Impacts reported R&D and G&A expense
NOLs and tax credits
Limits near-term tax benefit recognition

Actinium Pharmaceuticals, Inc.

ATNM · Pharmaceutical Preparations

CITIUS ONCOLOGY, INC.

CTOR · Pharmaceutical Preparations

Pyxis Oncology, Inc.

PYXS · Pharmaceutical Preparations

Boliden

BOL.ST · Basic Materials

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

ALX ONCOLOGY HOLDINGS INC

ALXO · Pharmaceutical Preparations

: 11/08/2026